Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi, Chuo-ku
Osaka
541-8505
142 articles about Mitsubishi Tanabe Pharma Corporation
-
Mitsubishi Tanabe Pharma America Announces Publication of Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuations
3/18/2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612.
-
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2024 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)
3/4/2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal , and virtually, from March 5-9.
-
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference
3/1/2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Manitoba
12/15/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that effective December 21, 2023, the Manitoba Pharmacare Program will cover RADICAVA® Oral Suspension for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.1
-
Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veteran Affairs Canada and Indigenous Services Canada
12/13/2023
Mitsubishi Tanabe Pharma Canada a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension for the treatment of amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease1, is now reimbursed by Veterans Affairs Canada and Indigenous Services Canada via the Non-Insured Health Benefits Program.
-
Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND
12/5/2023
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador
11/7/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Prince Edward Island Pharmacare Formulary and the Newfoundland and Labrador Prescription Drug Program for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Canadian-Developed AI Technology Aims to Support Early Detection of ALS
9/20/2023
Mitsubishi Tanabe Pharma Canada is proud to support the development of a new artificial intelligence program designed to analyze de-identified electronic medical records and identify individuals for which follow-up investigations for Amyotrophic Lateral Sclerosis, or referral to a specialty centre may be clinically appropriate.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Saskatchewan
9/1/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Saskatchewan Drug Plan Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in New Brunswick and Nova Scotia
8/29/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the New Brunswick Drug Plan formulary and the Nova Scotia Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in British Columbia
8/18/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under British Columbia PharmaCare for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Québec
8/16/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Régie de l'assurance maladie du Québec formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Announces Collaboration With the CNDR on First Canadian Real-World Evidence Study of Radicava® IV (Edaravone) Survival Benefits in ALS
8/9/2023
Mitsubishi Tanabe Pharma Canada publicly announced its collaboration with the Canadian Neuromuscular Disease Registry, an independent, academic registry based out of the University of Calgary, on the first Canadian real-world evidence generation study1 of RADICAVA® IV for the treatment of people with amyotrophic lateral sclerosis.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
8/3/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is covered, as of August 1, 2023, under the Alberta Drug Benefit List for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario
8/1/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Ontario Drug Benefit Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
-
Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent With Pan-Canadian Pharmaceutical Alliance for Radicava® Oral Suspension (Edaravone)
7/20/2023
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that it has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding RADICAVA® Oral Suspension, for the treatment of people with amyotrophic lateral sclerosis, which was authorized by Health Canada on November 8, 2022.
-
Mitsubishi Tanabe Pharma America Highlights Latest Research in Parkinson's Disease at EAN and WPC 2023 Congresses
7/5/2023
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of seven abstracts in Parkinson's disease (PD) at the 9th Congress of the European Academy of Neurology (EAN), which was held in Budapest, July 1-3 , and the 6th World Parkinson Congress (WPC), being held in Barcelona, July 4-7.
-
Mitsubishi Tanabe Pharma America to Partner with ALS/MND Natural History Study Consortium to Collect Real-World Data in ALS with the Goal of Improving Patient Care
6/6/2023
Mitsubishi Tanabe Pharma America, Inc. announced they are partnering with the ALS/MND Natural History Study Consortium to collect real-world data in amyotrophic lateral sclerosis in an effort to develop a better understanding of the disease and current care practices.
-
Mitsubishi Tanabe Pharma America Announces Presentations at XXVIII World Congress on Parkinson's Disease and Related Disorders
5/12/2023
Mitsubishi Tanabe Pharma America, Inc. announced two presentations on investigational ND0612 in Parkinson's disease will be shared at the International Association of Parkinsonism and Related Disorders XXVIII World Congress on Parkinson's Disease and Related Disorders, being held in Chicago, Ill., May 13-16.
-
Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.